FISCAL YEAR 2023-24 RESULTS

June 10, 2024

IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING

This presentation contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) the ability of its products to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this presentation relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's universal registration document, filed with the AMF on July 28, 2023, (the "Universal Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 27 of the Universal Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This presentation is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this presentation does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this presentation may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this presentation are encouraged to inquire about, and required to comply with, these restrictions

All information in the presentation speaks only as of (1) the date hereof, in the case of information about the Company and (2) the date of such information, in the case of information from persons other than the Company. The Company does not undertake any duty to update or revise the information contained herein, publicly or otherwise. The Company has not independently verified any third-party information and makes no representation as to the accuracy or completeness of any such information.

UZEDY®, $80M SALES GUIDANCE FOR 2024

UZEDY® Launch Building Momentum

UZEDY (risperidone)

Reaffirming 2024 revenues outlook of ~$80M

UZEDY Prescription Growth

UZEDY TRx MOT (months of therapy)



- Differentiated clinical profile we believe to be attractive to patients and HCPs
- Broad access in Fee-for-Service Medicaid
- Strong commercial effort to drive awareness, trial and adoption
- Sales coverage of hospitals, acute treatment centers and community mental health centers

Source: IQVIA NPA (TRx normalized into patient months of therapy equivalent volume based on dosing regimen), large LTC supplier stopped sending IQVIA TRx / NRx / NBRx data starting 7/7/23

teva

Source: Teva earnings call presentation - MAY 8, 2024

medincell

Olanzapine LAI

May be the first long-acting olanzapine with a favorable safety profile

- **Positive Phase 3 efficacy results**
- **No PDSS to date**

  80% of ca. 3600 injections required by FDA (May 8, 2024)

LONG-ACTING INJECTABLE PRODUCT PORTFOLIO AND R&D PIPELINE

MARKET

mdc-IRM
UZEDY®
Risperidone 1- & 2-Month
Schizophrenia
teva

CLINICAL PHASE 3

mdc-TJK
Olanzapine 1-Month
Schizophrenia
teva

mdc-CWM
Celecoxib - Intraarticular
Postoperative pain
AiC

PRECLINICAL

mdc-WWM
Progestin 6-Month
Contraception
BILL & MELINDA GATES foundation

mdc-STM
Ivermectin 3-Month
Malaria
Unitaid

FORMULATION

AbbVie (1/6)
abbvie

+9 in-house or partnered active programs

WAVE 1
WAVE 2
WAVE 3 & 4

medincell

STRATEGIC COLLABORATION WITH ABBVIE (APRIL 2024)

Co-development and licensing agreement

First program candidate selected; formulation activities underway

5 additional programs

$35 million upfront payment

up to **$1.9 billion**
in potential commercial and development milestones
(up to $315 million for each program)

Tiered mid-single to low-double digit royalties

SELECTED FINANCIALS

as of March 31, 2024

€ million	Year end *March 31, 2024*
Operating result	**(20.9)**
Revenues and other income	11.9
Operating expenses	(32.9)
Net result	**(25.0)**
Cash consumption from operating activities	**11.9**
Cash position	**19.5**[(1)]

(1) including 5.2 M€ in the form of non-risky financial assets

+ $35 million from AbbVie *(May 2024 – post-closing)*

medincell

UZEDY®, STRONG DIFFERENTIATION THANKS TO BEPO®

Subcutaneous injection (vs. Intramuscular)

No reconstitution needed

Immediate onset of action

(vs. oral supplementation or second injection needed)

Same effect regardless of location of injection

medincell

OLANZAPINE IS THE MOST PRESCRIBED ANTIPSYCHOTIC FOR SCHIZOPHRENIA IN THE U.S.

Olanzapine LAI Significant Potential

U.S. Schizophrenia Rx market, current atypical antipsychotic use





LAI	MoT TRx Share
Invega® LAIs (paliperidone)	61%
Aristada® (aripriprazole lauroxil) / Abilify® (aripiprazole)	34%
Risperdal Consta®/ Perseris®/UZEDY® (risperidone)	5%
Zyprexa® Relprevv™ (olanzapine)	<1%

Current Atypical Antipsychotic Use: IQVIA NPA Feb'24 MAT; (LAI TRx normalized into patient months of therapy equivalent volume based on dosing regimen), Oral atypical TRx share: company analysis
Global peak sales source: Evaluate pharma complete data extract for LAI antipsychotics
Trademarks mentioned are the property of their respective owners

Source: Teva earnings call presentation - MAY 8, 2024

medincell

OLANZAPINE LAI: POSITIVE PHASE 3 EFFICACY DATA

Screening

Eligibility Criteria

- Current confirmed diagnosis of schizophrenia according to the DSM-5, for >1 year
- Exacerbation of schizophrenia that started ≤8 weeks prior to screening and would benefit from psychiatric hospitalization or continued hospitalization for symptoms
- Treatment with antipsychotic (other than clozapine) in the past year and must have been responsive based on the investigator's judgment

640 PARTICIPANTS

Randomized
1:1:1:1

Period 1
8 weeks

TV 44749 Low dose → **-9.71 points [p<0.001]**

TV 44749 medium dose → **-11.27 points [p<0.001]**

TV 44749 high dose → **-9.71 points [p<0.001]**

Placebo

PANSS score reduction
mean difference in change vs. placebo from baseline to 8 weeks

Primary endpoint: Positive and Negative Syndrome Scale (PANSS) total score (Change from baseline to week 8)

Secondary endpoints include:

- Clinical Global Impression-Severity (CGI-S) scale
- Personal and Social Performance Scale (PSP)

Total score statistically significant
(adjusted for multiplicity)

medincell

OLANZAPINE LAI

No PDSS AS OF MAY 8, 2024

80% of ca. 3600 injections required by FDA

► **May be the first long-acting olanzapine with a favorable safety profile**

Intraarticular celecoxib

Postoperative inflammation and pain management

► **Encouraging Phase 3 results in Total Knee Replacement (May 2024)**

mdc-CWM, PHASE 3 RESULTS

Primary endpoint of time-weighted AUC of pain intensity over 14 days not met

Numerical improvement favoring the treated group observed for

- The primary endpoint
- Secondary endpoints of time-weighted AUC of pain over 3 and 7 days

Other positive outcomes related to inflammation

- Improvement for knee range of motion (ROM) at 6 weeks ($p<0.005$), as well as at 3 months ($p<0.0005$)
- Improvement for swelling at 6 weeks ($p<0.005$) and 3 months ($p<0.05$)
- Improvement of the Timed-Up-and-Go (TUG) test at 6 weeks

Far greater improvement in a sub-group of 108 patients

- Patients had not previously undergone TKR in their contralateral knee
- Improvement in endpoints of time-weighted AUC of pain, opioid consumption, ROM, effusion, and TUG

No new safety signals were identified, and no SAEs were reported as related to F14 treatment

What’s next?

WHAT'S NEXT IN 2024?

UZEDY®	Sales ramp up since commercial launch in May 2023	✓
Olanzapine LAI **mdc-TJK**	Positive Phase 3 efficacy results	✓
	No PDSS (3600 injections requested by FDA)	✓
Intraarticular celecoxib **mdc-CWM**	Encouraging Phase 3 results	✓
	Next development steps	✓
Partnering	Strategic collaboration with AbbVie	✓
	Other new collaborations	✓

NEW ERA, ACCELERATING GROWTH

Revenue ramp up from UZEDY® and Olanzapine LAI*

Execution of AbbVie and other ongoing collaborations

Taking advantage of wave of new CNS products

Move into new indications

Move into new types of molecules

* Provided FDA and/or other regulatory agencies approval

Q&A